
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is a promising clinical-stage biotechnology company with a portfolio of targeted therapies for multiple solid tumors, which is differentiated from other therapies through its comprehensive and unique mechanism of action. With positive Phase 3 PFS results in both PIK3CA WT and MT subgroups and a planned sNDA filing after the upcoming July PDUFA decision, the company is positioned for potential pan-PIK3CA coverage. Celcuity's decision to expand its 1L program with a simplified Phase 3 design and initiation of development for a subcutaneous formulation further solidify the company's growth potential. Despite the risks associated with clinical, technology, regulatory, manufacturing, commercial, legal and intellectual property, competition, and dilution, the company's impressive financials, including a projected 12-month price target of $185 per diluted share, make it a favorable investment opportunity.
Bears say
Celcuity is a clinical-stage biotechnology company that is focused on developing targeted therapies for multiple types of cancer. While the company's lead candidate, gedatolisib, shows promise in clinical studies, the competitive nature of the drug development industry and the need for additional funding present potential risks for the company's success. The company's financial outlook may also be impacted by its ability to receive milestone payments or attract partners.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares